SCIT with a high-dose house dust mite allergoid is well tolerated: safety data from pooled clinical trials and more than 10 years of daily practice analyzed in different subgroups
ConclusionSCIT with the marketed dose of high-dose HDM allergoid was well tolerated in clinical development and in daily practice. There was no increased risk for the investigated patient subgroups. Tolerability was comparable to HDM sublingual immunotherapy (SLIT) tablets.
Source: Allergo Journal International - Category: Allergy & Immunology Source Type: research
More News: Allergy & Immunology | Asthma | Child Development | Children | Clinical Trials | Drugs & Pharmacology | Hay Fever | Immunotherapy | Respiratory Medicine